1-7 of 7
Daniel J. DeAngelo
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

Evan C. Chen, Helen Gandler, Isidora Tošić, Geoffrey G. Fell, Ashlee Fiore, Olga Pozdnyakova, Daniel J. DeAngelo, Ilene Galinsky, Marlise R. Luskin, Martha Wadleigh, Eric S. Winer, Rebecca Leonard, Kelsey O'Day, Adrienne de Jonge, Donna Neuberg, A. Thomas Look, Richard M. Stone, David A. Frank, Jacqueline S. Garcia
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (5): 878–887.
https://doi.org/10.1158/1078-0432.CCR-22-2540
Published: 01 March 2023
View article titled, Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Open the PDF for Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates in another window
Includes: Supplementary data
Journal Articles

Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia

Eytan M. Stein, Daniel J. DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Chia-Chi Lin, Cristina Suarez, Filip de Vos, Neeltje Steeghs, Philippe A. Cassier, David Tai, Jean-Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stephane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (5): 870–881.
https://doi.org/10.1158/1078-0432.CCR-21-1295
Published: 01 March 2022
View article titled, Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia
Open the PDF for Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <em>TP53</em> Solid Tumors and Acute Leukemia in another window
Includes: Supplementary data
Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2742–2754.
https://doi.org/10.1158/1078-0432.CCR-20-2399
Published: 15 May 2021
View article titled, Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
Open the PDF for Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 in another window
Includes: Supplementary data
Journal Articles

A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets

Sophia Adamia, Benjamin Haibe-Kains, Patrick M. Pilarski, Michal Bar-Natan, Samuel Pevzner, Herve Avet-Loiseau, Laurence Lode, Sigitas Verselis, Edward A. Fox, John Burke, Ilene Galinsky, Ibiayi Dagogo-Jack, Martha Wadleigh, David P. Steensma, Gabriela Motyckova, Daniel J. Deangelo, John Quackenbush, Richard Stone, James D. Griffin
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (5): 1135–1145.
https://doi.org/10.1158/1078-0432.CCR-13-0956
Published: 02 March 2014
View article titled, A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets
Open the PDF for A Genome-Wide Aberrant RNA Splicing in Patients with Acute Myeloid Leukemia Identifies Novel Potential Disease Markers and Therapeutic Targets in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia

Eyal C. Attar, Daniel J. DeAngelo, Jeffrey G. Supko, Ferdinando D'Amato, David Zahrieh, Andres Sirulnik, Martha Wadleigh, Karen K. Ballen, Steve McAfee, Kenneth B. Miller, James Levine, Ilene Galinsky, Elizabeth G. Trehu, David Schenkein, Donna Neuberg, Richard M. Stone, Philip C. Amrein
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1446–1454.
https://doi.org/10.1158/1078-0432.CCR-07-4626
Published: 03 March 2008
View article titled, Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia
Open the PDF for Phase I and Pharmacokinetic Study of Bortezomib in Combination with Idarubicin and Cytarabine in Patients with Acute Myelogenous Leukemia in another window
Journal Articles

Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation: Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism without Graft- versus -Host Disease

Daniel J. DeAngelo, Ephraim P. Hochberg, Edwin P. Alyea, Janina Longtine, Stephanie Lee, Ilene Galinsky, Ben Parekkedon, Jerome Ritz, Joseph H. Antin, Richard M. Stone, Robert J. Soiffer
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5065–5071.
https://doi.org/10.1158/1078-0432.CCR-03-0580
Published: 05 August 2004
View article titled, Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation: <subtitle>Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism without Graft- <em>versus</em> -Host Disease</subtitle>
Open the PDF for Extended Follow-up of Patients Treated with Imatinib Mesylate (Gleevec) for Chronic Myelogenous Leukemia Relapse after Allogeneic Transplantation: <subtitle>Durable Cytogenetic Remission and Conversion to Complete Donor Chimerism without Graft- <em>versus</em> -Host Disease</subtitle> in another window
Journal Articles

Imatinib Therapy for Patients with Chronic Myelogenous Leukemia: Are Patients Living Longer?

Daniel J. DeAngelo, Jerome Ritz
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (1): 1–3.
https://doi.org/10.1158/1078-0432.CCR-1218-3
Published: 20 January 2004
View article titled, Imatinib Therapy for Patients with Chronic Myelogenous Leukemia: <subtitle>Are Patients Living Longer?</subtitle>
Open the PDF for Imatinib Therapy for Patients with Chronic Myelogenous Leukemia: <subtitle>Are Patients Living Longer?</subtitle> in another window